AKT1 and breast carcinoma: As luminal subtype of breast cancer has activation of the PI3K/AKT pathway and the effect of monotherapy of PI3K/AKTis is moderate17, we sought to identify additional strategies that may increase the efficacy of AKTi by rational combination therapies that will increase synergy and overcome emergence of resistance.